

FY2020 Financial Results for the 3rd Quarter

Sawai Pharmaceutical Co., Ltd.

4555.T, TSE 1st section

Feb 12, 2021

- Japan: Sales and operating income increased year-over-year due to an increase in sales of new products, despite the impact of patients refraining from seeking medical attention due to COVID-19, the reduction in the number of flu patients, and the impact of two NHI drug price revisions.
- United States: Sales and operating income decreased due to the negative impact of COVID-19 on acute brand prescriptions and the entry of competitors to existing products.
- Consolidated: Profit is on track to achieve forecast.

J1 1, W									JP I, MM	
	I	FY 2019 3Q			FY 2020 3Q		Yo	Y	FY2(020
		by Re	gion		by Re	egion			Full Year	Forecast
		Japan	US		Japan	US	+/-	Growth	Mil. yen	/Sales (%)
Net Sales	140,266	110,810	29,456	142,697	115,940	26,757	2,430	1.7%	200,200	71.3%
Operating Income	23,944	21,045	2,899	22,850	22,786	64	-1,094	-4.6%	26,850	85.1%
Profit before tax	23,785		_	22,595	_	_	-1,190	-5.0%	26,550	85.1%
Profit attributable to owners of the parent	17,319		_	17,388	_	_	69	0.4%	20,050	86.7%
Core Operating Income *	29,166	22,238	6,902	28,341	24,334	3,995	-825	-2.8%	34,800	81.4%


*With the adoption of IFRS, we have introduced "Core Operating Income" as an indicator of recurring profitability, and we regard this as a key indicator

of business performance that excludes non-recurring factors from operating income

Average rate	FY2019 3Q Actual	FY2020 3Q Actual
1 US dollar	109	106

IPV MM

sawa



Sales by Channel, Japan (Unconsolidated)

Sales in the hospital sector were affected by patients refraining from seeking medical attention, due to COVID-19, in addition to the impact of two NHI drug price revisions.
 Sales increased steadily due to the adoption of new products in the pharmacy sector.

	Total,	FY 20	19 3Q]	FY 2020 3Q		Y	οY
Channel	Nationwide	# of Customers	Sales Share	# of Customers	Coverage Rate	Sales Share	# of Customers	Sales Growth
Hospital	8,270	8,073	11.7%	8,036	97.2%	10.8%	-37	-4.7%
DPC* Hospital	1,757	1,717	7.1%	1,749	99.5%	6.6%	32	-4.0%
Clinic	106,194	37,969	9.2%	38,541	36.3%	8.9%	572	0.3%
Pharmacy	89,199	58,674	77.8%	59,419	66.6%	79.1%	745	5.4%
Dispensing	61,948	58,360	77.2%	59,107	95.4%	78.5%	747	5.4%
Drug Stores, etc.	27,251	314	0.6%	312	1.1%	0.6%	-2	-5.2%
Others	-	-	1.3%	-	-	1.2%	-	-3.8%
Total	203,663	104,716	100.0%	105,996	52.0%	100.0%	1,280	3.4%

*DPC: Diagnosis Procedure Combination, a fixed payment system for inpatients

Sales by Product Launch Year, Japan

• Steady sales growth for new products launched in FY2020, mainly in categories with few competitors.

							JPY, MM
50,000				Year Launched	FY 2019 3Q	FY 2020 3Q	YoY
45,000				FY2020	-	9,363	-
40,000		9,36	3	FY2019	205	1,413	587.5%
35,000	205	1,41	3	FY2018	6,175	5,068	-17.9%
30,000	6.175	5.06	8	FY2017	5,374	5,210	-3.0%
25,000	5.374	5.21		FY2016	1,232	1,301	5.7%
20,000	4,733	1,30 4,86		FY2015	4,733	4,862	2.7%
15,000		3,33	6	FY2014	3,364	3,336	-0.8%
10,000	3,883	3,72		FY2013	3,883	3,725	-4.1%
5,000	6,103	3,46		FY2012	3,322	3,461	4.2%
0		I		FY2011	6,103	5,759	-5.6%
	FY 2019 3Q	FY 2020		Launced before FY2010	76,419	72,442	-5.2%
	FY2011 FY2012 FY2016 FY2017	 ■ FY2013 ■ FY2014 ■ FY2018 ■ FY2019 	FY2015	Total	110,810	115,940	4.6%




. .

Overall sales decreased due to the negative impact of COVID-19 on acute brand prescriptions and new competitor entries into key USL generic product markets.
 As of Q3 2020, Vigadrone is now USL's third largest product.

			JPY, MM	By the	rapeutic a	areas	
	FY2019	FY2	020			FY2020 3Q	FY2020 1H YoY Sales
	3Q Actual	3Q Actual	Forecast (Full Year)	Central nervous system	44.9%	51.8%	+4.9%
	05.410	20.121		Cardiovascular	38.6%	32.2%	-24.2%
Existing products	25,419	20,131	29,500	Agents for urogenital and rectal systems	3.8%	4.7%	+13.3%
New products ^{*1}	4,037	6,626	11,100	Hormone preparations	4.9%	3.2%	-40.3%
				Antineoplastic agents	2.7%	1.9%	-35.5%
Total	29,456	26,757	40,600	The others	5.1%	6.2%	+7.9%
2				Total	100.0%	100.0%	-9.2%
Brand products ^{*2} (Reference)	5,421	5,315					

*¹ Sales of products launched since FY2018

 $*^2$ Sales of Qudexy[®], Zembrace[®] Symtouch[®] and TosymraTM



 Our full-year forecast remains unchanged as the circumstances surrounding the business environment is unclear, considering the impact of COVID-19 etc.


	FY20 3Q Act		F Full Ye	ast	
	Mil. yen	/S ales (%)	Mil. yen		/S ales (%)
Net Sales	142,697	100.0%	200,200	100.0%	71.3%
Operating Income	22,850	16.0%	26,850	13.4%	85.1%
Profit before tax	22,595	15.8%	26,550	13.3%	85.1%
Profit attributable to owners of the parent	17,388	12.2%	20,050	10.0%	86.7%
Core Operating Income	28,341	19.9%	34,800	17.4%	81.4%
		Aver	rage rate FY202 Act		FY2020 ssumption
		1 U	S dollar	106	110



Reference Materials

Sales by Distribution Channel, Japan

Sales through wholesalers increased due to newly launched products.



Comparison of Sales Volume by therapeutic area, Japan

- Steady growth in CNS (Central Nervous System) and Vitamin lines.
- Volume reductions of more than 20% for respiratory organ agents and antibiotics due to the decline in the number of visits patients made to Pediatric and Otolaryngology offices.

	Volume Co	omposition			
The rape utic Category	FY2019 3Q	FY2020 3Q	YoY (volume)	YoY (value)	
Cardiovascular drugs	29.3%	29.8%	7.3%	1.4%	
Gastro-intestinal drugs	19.6%	18.6%	0.4%	-3.3%	
Central nervous system drugs	13.1%	13.4%	7.8%	22.1%	
Blood/body fluid pharmaceutical products	8.4%	8.3%	3.1%	1.3%	
Other metabolic drugs	6.2%	6.9%	17.8%	19.5%	
Vitamin drugs	3.9%	5.6%	51.6%	270.4%	
Respiratory organ agents	6.9%	5.2%	-20.0%	-15.8%	
Antibiotics drugs	2.5%	1.9%	-21.1%	-19.3%	
Antineoplastic agents	0.4%	0.4%	11.7%	-3.3%	
Others	9.7%	9.9%	7.2%	-5.7%	
Total	100.0%	100.0%	5.4%	4.6%	



Consolidated Financial Highlights-1

								JPY, MM
	FY2019	3Q	FY2020 3Q			FY2020 Forecast		
		/Sales(%)		/Sales (%)	YoY(%)	Full Year	/Sales (%)	YoY (%)
Key Income Statements Data								
Net Sales	140,266	100.0	142,697	100.0	1.7	200,200	100.0	9.7
Cost of Sales	83,138	59.3	85,909	60.2	3.3	119,600	59.7	9.7
Gross Profit	57,128	40.7	56,788	39.8	-0.6	80,600	40.3	9.7
SG&A Expenses	24,013	17.1	24,857	17.4	3.5	36,400	18.2	9.1
R&D Expenses	9,470	6.8	9,312	6.5	-1.7	17,600	8.8	30.5
Other income(expenses)	298	0.2	231	0.2	-22.4	250	0.1	60.7
Operating Income	23,944	17.1	22,850	16.0	-4.6	26,850	13.4	0.2
Profit before tax	23,785	17.0	22,595	15.8	-5.0	26,550	13.3	0.2
Profit attributable to owners of the parent	17,319	12.3	17,388	12.2	0.4	20,050	10.0	4.0
Core operating income	29,166	20.8	28,341	19.9	-2.8	34,800	17.4	1.2
EBITDA [*]	37,886	27.0	36,970	25.9	-2.4	46,800	23.4	1.4

* Core operating income + amortization and depreciation expenses included in core operating income + impairment charges

	As of March 31, 2019	As of Dec 31, 2020
Key Balance Sheets Data		
Total Assets	384,814	390,865
Equity	233,686	239,363
Ratio of equity attributable to owners of the company to total assets (%)	54.6	55.5

	FY2019 3Q	FY2020 3Q	FY2020 Full Year Forecast
Amounts Per Common Share			
Basic earnings per share	395.59	397.11	457.85
Diluted earnings per Share	395.27	396.71	_
Dividend (interim)	(65.0)	(65.0)	130.0



Consolidated Financial Highlights-2

Sales and Operating Income by Area

Japan

	FY2019	3Q	FY	2020 3Q		FY2020 Ful	l Year Fo	orecast
Key Income Statements Data		/Sales (%)		/Sales (%)	YoY (%)		/Sales (%)	YoY (%)
Net Sales	110,810	100.0	115,940	100.0	4.6	159,600	100.0	10.7
Cost of Sales	70,433	63.6	72,642	62.7	3.1	101,000	63.3	10.0
Gross Profit	40,377	36.4	43,297	37.3	7.2	58,600	36.7	12.1
SG&A Expenses	14,538	13.1	15,460	13.3	6.3	23,100	14.5	12.7
R&D Expenses	5,031	4.5	5,084	4.4	1.1	10,200	6.4	35.1
Other income(expenses)	237	0.2	34	0.0	-85.8	0	_	_
Operating Income	21,045	19.0	22,786	19.7	8.3	25,300	15.9	3.7
Core operating income	22,238	20.1	24,334	21.0	9.4	28,000	17.5	5.7
EBITDA *	30,163	27.2	32,166	27.7	6.6	38,000	23.8	2.3

US

	FY2019	FY2019 3Q		2020 3Q		FY2020 Full Year Forecast		
Key Income Statements Data		/Sales (%)		/Sales (%)	YoY (%)		/Sales (%)	YoY (%)
Net Sales	29,456	100.0	26,757	100.0	-9.2	40,600	100.0	5.7
Cost of Sales	12,705	43.1	13,267	49.6	4.4	18,600	45.8	8.3
Gross Profit	16,751	56.9	13,490	50.4	-19.5	22,000	54.2	3.6
SG&A Expenses	9,474	32.2	9,407	35.2	-0.7	13,300	32.8	3.1
R&D Expenses	4,465	15.2	4,229	15.8	-5.3	7,400	18.2	24.3
Other income(expenses)	87	0.3	210	0.8	142.0	250	0.6	_
Operating Income	2,899	9.8	64	0.2	-97.8	1,550	3.8	-35.1
Core operating income	6,902	23.4	3,995	14.9	-42.1	6,800	16.7	-13.7
EBITDA *	7,697	26.1	4,793	17.9	-37.7	8,800	21.7	-1.9

* Core operating income + amortization and depreciation expenses included in core operating income + impairment charges

Consolidated Financial Highlights-3

Adjusted from Full basis to Core basis

JPY, MM

		Full Basis	Adjusting (Japan)	Adjusting (US)	Core Basis	Full Basis	Adjusting (Japan)	Adjusting (US)	Core Basis
Net Sales		140,266	—		140,266	142,697	—		142,697
Cost of Sale	es	-83,138	47	99	-82,992	-85,909	348	35	-85,526
	Inventory step-up	-104	_	104		-25	_	25	—
	Impairment loss	—	_	—	—	—	_	_	—
	Others	_	47	-5	_	-507	348	9	—
Gross Profit	t	57,128	_	99	57,274	56,788	348	35	57,170
SG&A Expe	enses	-24,013	396	3,057	-20,559	-24,857	397	3,513	-20,947
	Amortization of intangible assets	-3,453	396	3,057		-3,913	396	3,517	—
R&D Expen	ises	-9,470	988	934	-7,549	-9,312	837	593	-7,883
	Amortization of intangible assets	-1,056	524	531		-1,252	708	543	—
	Impairment loss	-865	463	402		-177	128	49	_
Other incon	ne	409	-344	-65		275	-70	-205	
Other exper	ises	-111	107	4		-44	41	3	
Operating I	ncome	23,944	1,193	4,029	29,166	22,850	1,552	3,938	28,341

Consolidated Financial Data

								JPY, MM
Selling General and		FY2019 3Q		FY	2020 3	Q	FY2020 Full Year Forecast	
Administrative 1	Administrative Expenses		/Sales(%)		/Sales (%)	YoY(%)		/Sales (%)
	Japan	5,031	4.5	5,084	4.4	1.1	10,200	6.4
R&D Expenses	US	4,465	15.2	4,229	15.8	-5.3	7,400	18.2
	Total	9,470	6.8	9,312	6.5	-1.7	17,600	8.8
Advertisemet Expenses	Total	1,863	1.3	1,802	1.3	-3.3	2,900	1.4

Capital Expen Depreciation an		FY2019 3Q	FY 2020 3Q	FY2020 Full Year Forecast
Capital	Japan	2,454	5,794	7,500
-	US	1,643	5,116	6,800
Expenditure	Total	4,097	10,910	14,300
Depreciation and Amortization	Japan	8,845	8,935	11,500
	Manufacturing Division	6,252	6,230	8,300
	R&D Division Administration	1,339	1,471	1,500
	Div. & Rusiness Div	1,255	1,234	1,700
	US	4,384	4,859	6,900
	Total	13,229	13,794	18,400

Personnel Information	As of Dec 31	1,2019	As of Dec 31, 2020		
Number of Employees		Comp.(%)		Comp.(%)	
Japan	2,522	81.3	2,677	80.9	
Manufacturing Division	1,667	53.8	1,616	53.2	
R&D Division	253	8.2	248	8.2	
Administration Div. & Business Div.	602	19.4	595	19.6	
(MRs)	(400)		(385)		
US	579	18.7	579	19.1	
Total	3,101	100.0	3,038	100.0	

Copyright © 2021 Sawai Pharmaceutical Co., Ltd. All Rights Reserved.

Disclaimer

- The plans, forecasts, strategy and other information regarding the Sawai Group contained in this presentation are based on the Company's assumptions and judgments using information available at the time of publication. Therefore, due to potential risks and uncertainties, there is no guarantee of the accuracy of this information.
- Potential risks and uncertainties include, but are not limited to, the economic environment for prescription drugs, which is the main operating domain of the Sawai Group, market competition and services offered by the Group.

Contact Information

Sawai Pharmaceutical Co., Ltd. Public Relations & Investor Relations Office E-mail: **ir@sawai.co.jp**